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Abstract
Background: The prevalence of multimorbidity is increasing worldwide, presumably leading to an increased use of
medicines. During the last decades the use of hypnotic and anxiolytic benzodiazepine derivatives and related drugs has
increased dramatically. These drugs are frequently prescribed for people with a sleep disorder often merely designated as
“insomnia” in the medical records and lacking a clear connection with the roots of the patients’ problems. Our aim was to
analyse the prevalence of multimorbidity in primary healthcare in Iceland, while concurrently investigating a possible
association with the prevalence and incidence of hypnotic/anxiolytic prescriptions, short-term versus chronic use.
Methods: Data were retrieved from a comprehensive database of medical records from primary healthcare in Iceland
to find multimorbid patients and prescriptions for hypnotics and anxiolytics, linking diagnoses (ICD-10) and prescriptions
(2009–2012) to examine a possible association. Nearly 222,000 patients, 83 % being local residents in the capital area, who
contacted 16 healthcare centres served in total by 140 general practitioners, were set as a reference to find the
prevalence of multimorbidity as well as the prevalence and incidence of hypnotic/anxiolytic prescriptions.
Results: The prevalence of multimorbidity in the primary care population was 35 %, lowest in the young, increasing with
age up to the 80+ group where it dropped somewhat. The prevalence of hypnotic/anxiolytic prescriptions was 13.9 %.
The incidence rate was 19.4 per 1000 persons per year in 2011, and 85 % of the patients prescribed hypnotics/anxiolytics
were multimorbid. Compared to patients without multimorbidity, multimorbid patients were far more likely to be
prescribed a hypnotic and/or an anxiolytic, OR = 14.9 (95 % CI = 14.4–15.4).
Conclusions: Patients with multiple chronic conditions are common in the primary care setting, and prevalence and
incidence of hypnotic/anxiolytic prescriptions are high. Solely explaining use of these drugs by linear thinking, i.e. that
“insomnia” leads to their prescription is probably simplistic, since the majority of patients prescribed these drugs are
multimorbid having several chronic conditions which could lead to sleeping problems. However, multimorbidity as such
is not an indication for hypnotics, and doctors should be urged to greater caution in their prescribing, bearing in mind
non-pharmacological therapy options.
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Background
In recent years the extensive research on the epidemiology
of multimorbidity in several countries has revealed that it is
an extremely common problem, not least in primary
healthcare where the majority of patients have more than
one problem at any given time [1–3]. The percentage of
patients with multiple diagnoses increases as people get
older. However, the extent of multimorbidity in young
people and even in children is perhaps greater than might
be expected, probably because risk factors for multiple
diseases are not randomly distributed [1, 4]. Multimorbidity
can be measured in several different ways and the range of
diseases included varies between studies. A recent study
with health data classified according to ICPC-2 chapters
(International Classification of Primary Care, Version 2),
ICD-10 chapters (International Classification of Diseases,
10th edition) or CIRS domains (Cumulative Illness Rating
Scale) found that when multimorbidity is defined as two or
more disease entities, prevalence estimates are similar, no
matter what diagnostic classification system is used [5].
Multimorbidity has been associated with polypharmacy
[6] and lower socioeconomic status [7]. Studies have
shown that clustering of diseases or conditions in persons
with multimorbidity is complex and does not follow any
typology [8–10]. This could indicate a common root of
chronic biological dysregulation in the body, better de-
scribed as allostatic overload, i.e. a physiological scenario
where the organism’s adaptive and restorative capacity is
overtaxed [8, 10].
A number of diseases are correlated with insomnia and
thus increasing multimorbidity might lead to an increase in
sleep disorders. Hypnotic and anxiolytic benzodiazepine
derivatives are commonly prescribed to people with a sleep
disorder often just labelled with the diagnosis “insomnia” in
the medical records. However, in epidemiological studies
on prescribing habits it is not always obvious what type of
health problems lie behind or are possibly connected with
prescribing hypnotic and anxiolytic drugs. This can be of
great importance in the primary care setting as a holistic
view of a patient’s health problems is usually put in focus.
Since the launching of chlordiazepoxide in 1960 and
diazepam a few years later the number of benzodiazepine
derivatives and related drugs released on the market has
multiplied and their use both as anxiolytics and hypnotics
increased dramatically [11]. Now they are some of the
most widely prescribed drugs. This has caused much con-
troversy with widely divided opinions, e.g. concerning
adverse effects, dependence, abuse liability, efficacy and
tolerability [11]. The serious side effects of benzodiazepines
have been known for decades [12], and in recent years, con-
cerns have been raised about possible links between the use
of these drugs and increased mortality [13–16]. Neverthe-
less, an incontestable evidence of a causal relationship has
not yet been presented, and findings in other studies have
not lent support to a strong association of hypnotic use with
excess mortality [17, 18]. A recently published prospective
study found that the risk of mortality was not significantly
associated with hypnotic use regardless of type and duration
[19] while a retrospective cohort study which also corrected
for a range of potential confounders found an association
with significantly increased risk of mortality [20]. In a newly
published study connecting disease burden and use of
hypnotics, it was shown that there was a 50 % increase in
the use of benzodiazepines 24 months before death. It was
concluded that the association between use of these drugs
and mortality is at least partially due to confounding [21].
Apart from the well-known risk of falls and fractures, there
are other untoward effects such as a possible association
with increased suicide risk [15, 22], increased risk of road
traffic accidents [23], dementia [24] and Alzheimer’s disease
[25]. Besides, the effectiveness of the newer type of hyp-
notics, the so-called Z drugs (zolpidem, zopiclone) has been
questioned [26]. Thus, there are numerous risks associated
with the use of these drugs which to some degree might be
avoided by using other treatment options for insomnia in-
stead of prescribing hypnotics. Sleep hygiene recommenda-
tions could be applied as first-line therapy [27] followed by
interventions needing more specialised skills such as cogni-
tive behavioural therapy [28].
The question might be raised whether patients with a
heavy disease burden are more prone to becoming chronic
users as sleeping problems leading to hypnotics being pre-
scribed, may be a direct consequence of multimorbidity,
although multimorbidity as such is not an indication for
the prescription of these drugs. In a paper on the medical-
isation of sleeplessness it was shown that during the study
period insomnia diagnoses increased more than sevenfold
while prescriptions for non-benzodiazepine sedative hyp-
notics (Z-drugs and ramelteon) increased about thirtyfold
[29]. It is known that the use of benzodiazepine derivatives
and related drugs increases with age [11] and also that the
prevalence of multimorbidity increases significantly with
age both in men and women [5–7]. It is also worth noting
that in a study comparing measures of multimorbidity to
predict outcomes in primary care, the number of drugs
prescribed was a powerful predictor of mortality [30].
There have not been many studies on the relationship be-
tween selected drug classes and multimorbidity, but it has
been shown that comorbidity was a correlate of benzodi-
azepine use in patients with depressive and/or anxiety
disorders [31]. Although several epidemiological studies
on multimorbidity have been done, there are still many
countries, including Iceland until now, where little is still
known about the prevalence of multimorbidity.
The aim of this study was firstly to analyse the prevalence
of multimorbidity in primary healthcare, and secondly to
analyse the prevalence and incidence of prescriptions of
hypnotics and anxiolytics, mostly benzodiazepine derivatives
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and Z-drugs, in order to find a possible association between
the use of these drugs and the prevalence of multimorbidity,
based on the assumption that sleeping problems and disease
discomfort related to multimorbidity might lead to prescrip-
tion of these drugs although a clear-cut indication might be
lacking. Thirdly, our aim was to find if incident patients took
the drugs according to clinical guidelines (2–4 weeks) or if
they had become either intermittent or regular users, thus
indicating the possibility that multimorbidity might be a
contributing factor in the chronic use of these drugs.
Methods
Design and setting
The Primary Health Care of the Capital Area (PHCCA)
includes most of the primary healthcare centres in Reykja-
vik and nearby municipalities with a population of just
over 200,000 serving general practice, maternity and well-
child care, and is staffed by general practitioners (GPs),
midwives, nurses and other personnel. The PHCCA oper-
ates a primary healthcare database of medical records
from 16 healthcare centres including both prescriptions
and diagnoses (ICD-10). Our study population, of whom
83 % had a postal code within the capital area, were all
patients who contacted in total 140 GPs at these health-
care centres during a period of 4 years. All contacts with
the primary healthcare centres were included in the study
covering, in our judgement, the vast majority of primary
care patients with multimorbidity and similarly primary
care patients who were prescribed hypnotics/anxiolytics in
the total population of the capital area.
A unique personal identifier (ID) is allocated to every
inhabitant and this personal ID number is always entered
when any information about a patient is recorded in the
medical records database making it possible to link all
stored information about the patient through the ID, and
in our study making it possible to uniquely link diagnoses
with prescriptions issued for a particular patient.
In this paper multimorbidity is defined as two or more
concurrent chronic diseases within one patient [1–3].
Selected ICD-10 diagnoses for chronic conditions [8] as
shown in Table 1, and data on the age and sex were ex-
tracted for all patients who consulted their family phys-
ician at any primary healthcare centre during the period
1 Jan 2009 to 31 Dec 2012 in order to find patients with
multimorbidity.
Prescriptions for hypnotics and anxiolytics from 1 Jan
2009 to 31 Dec 2012 were extracted from the medical
records in order to find both their prevalence and incidence
in the primary care patients, and to find the distribution
according to age and sex. We defined incident patients as
new users who had neither been prescribed a hypnotic nor
an anxiolytic the previous 24 months [32]. Thus, a four-
year period was needed for the purpose of calculating the
incidence. We estimated drug consumption to be either in
agreement with clinical guidelines (2–4 weeks) if there was
only one prescription, intermittent if they were 2–4, or
regular if the prescriptions were five or more during a 12
month period. Diagnoses for these patients were found by
linking the information on both the prescriptions and the
diagnoses in the medical records through the patient ID.
Thus it was possible to find multimorbid patients, patients
with one chronic condition and those who had no chronic
diagnosis in this group of patients.
After having extracted these data the remaining patients
in the primary healthcare database cohort had neither any
chronic condition pertaining to the multimorbidity defin-
ition nor had they been prescribed any hypnotics/anxio-
lytics. We used all patients who contacted the healthcare
centres during the same period (1 Jan 2009 to 31 Dec 2012)
as a reference group when the prevalence was calculated
for the multimorbidity and the hypnotics/anxiolytics pre-
scriptions, respectively. Data on the mean age of the total
population in Iceland was drawn from Statistics Iceland
and compared with the PHCCA cohort [33].
Collection of data on prescribed medications
Data on all medications classified in the Anatomical Thera-
peutic Chemical (ATC) classification system [34] as either
anxiolytics (ATC classification N05B) or hypnotics and
sedatives (ATC classification N05C) prescribed by general
practitioners for their patients were extracted from the pri-
mary healthcare database as described in a previous study
[35]. After collecting the data they were encrypted so the
personal identity of the patients would not be revealed dur-
ing the processing of the data set.
Data analysis
The prevalence of the use of hypnotics/anxiolytics,
mostly benzodiazepine and benzodiazepine-related drugs
(Z-drugs) in the general population consulting the
primary healthcare centres in the capital area was de-
termined throughout the period from 1 Jan 2009 to 31
Dec 2012. The incidence was determined for patients
initiating therapy in 2011 according to the above men-
tioned definition. The incidence is presented as number
of cases per 1000 persons per twelvemonth period. Both
the prevalence and the incidence were calculated accord-
ing to age and sex. The number of patients prescribed
hypnotics/anxiolytics was counted as well as the number
of patients in this cohort who had multimorbidity.
To address a part of the clinical picture among multi-
morbid patients who initiated use of hypnotics/anxio-
lytics in 2011, and sorting them by diagnoses, we pooled
together the diagnoses from Table 1 into three groups, i.e.
mental disorders (ICD-10: F00-F99), pain related diagnoses
(ICD-10: M00-M03, M05-M43, M45-M51, M53-M54,
M60-M77, M79-M99 and N18-N19) and the rest of the
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diagnoses in Table 1 which we placed in a group called other
diagnoses.
We used logistic regression to calculate age and sex
specific odds ratios (OR) and 95 % confidence intervals
(CI) for the likelihood of incident hypnotic/anxiolytic
drug use, stratified by age and sex, during the period
from 1 Jan 2009 to 31 Dec 2012, comparing those with
and without multimorbidity during a 12 month period.
Statistical analyses were conducted with Stata Release 13
(College Station, TX: StataCorp LP). Alpha level for stat-
istical significance was set at 0.05.
Results
A total of 221,822 patients contacted the primary health-
care centres during the period 1 Jan 2009 to 31 Dec 2012
or approximately two-thirds of the Icelandic population,
83 % being local residents. Table 2 shows the subset of
patients with multimorbidity compared with the total
cohort. Approximately 47 % of the total population did
not have any relevant chronic condition as defined in
Table 1, nearly 18 % had one chronic condition and 35 %
were considered as having multimorbidity. The prevalence
increased with age in both sexes up to 79 years of age.
During this four-year period a total of 30,926 patients
were prescribed hypnotics/anxiolytics (prevalence: 13.9 %;
10.1 % for men and 17.5 % for women). The prevalence of
hypnotics/anxiolytics prescriptions stratified for age and sex
is shown in Table 3. It increases steadily with increasing age
in both sexes until the highest age group is reached where
it drops slightly.
In 2011 there were 4305 patients who had not been
prescribed hypnotics/anxiolytics the two previous years
who initiated treatment for insomnia or anxiety with a
new prescription, hence categorised as incident patients.
During a 12 month period approximately 56 % received
one prescription only, 33 % received 2–4 prescriptions,
and nearly 11 % of the patients were issued 5 prescrip-
tions or more.
Table 1 Chronic medical diseases/conditions according to ICD-10
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Epilepsy G40




















Table 2 Number of patients and prevalence of multimorbidity
Age
groups
All patients contacting the PHCCA Patients with multimorbidity (number and %)
All Men Women All % Men % Women %
<1–19 61,033 30,982 30,051 6,157 10 3,156 10 3,001 10
20–29 34,255 15,950 18,305 8,250 24 3,174 20 5,076 28
30–39 33,291 16,310 16,981 11,077 33 4,480 27 6,597 39
40–49 27,619 13,498 14,121 12,934 47 5,406 40 7,528 53
50–59 25,300 12,398 12,902 14,657 58 6,456 52 8,201 64
60–69 19,159 9,351 9,808 11,955 62 5,578 60 6,377 65
70–79 11,166 5,197 5,969 7,637 68 3,440 66 4,197 70
80+ 9,999 4,103 5,896 5,493 55 2,275 55 3,218 55
Total 221,822 107,789 114,033 78,160 35 33,965 32 44,195 39
All patients contacting the Primary Health Care of the Capital Area (PHCCA) during a period of 4 years (1 Jan 2009 to 31 Dec 2012) and prevalence of multimorbidity
according to age and sex
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Results for the incidence of hypnotics/anxiolytics pre-
scriptions per 1000 persons per year in 2011 according to
age and sex are shown in Table 4. The incidence increased
with age and was higher in women than in men. Table 5
shows the division into 1 prescription, 2–4 prescriptions
and 5+ prescriptions categories, both for all incident
patients and the subset of incident multimorbid patients.
The proportion of incident patients who received either
one, 2–4 or 5+ prescriptions respectively during the 12
month period are plotted in Fig. 1.
Figure 2 illustrates some aspects of the clinical profile
among the multimorbid incident patients subdivided into
those who are either one time, intermittent or regular
users. As shown, the combination of mental disorders and
pain related diagnoses dominate the patient profile. Most
often the use of these drugs was sporadic.
In the group of patients who were prescribed hyp-
notics/anxiolytics (30,926), 3 % (1018) had no chronic
condition, 12 % (3693) had only one chronic condition
while 85 % (26,215) were categorised as being multimor-
bid. Their distribution according to age, sex and number
of conditions can be seen in Table 6 with the ORs for
the likelihood of being prescribed a hypnotic and/or an
anxiolytic if multimorbid. Figure 3 shows this group
according to age and number of conditions and Fig. 4
shows the ORs by age and sex.
In this four-year period the total number of anxiolytics
prescribed was 1.92 million defined daily doses (DDDs)
[34], thereof 93 % benzodiazepines. During the same
time 5.87 million DDDs of hypnotics were prescribed,
11 % benzodiazepines and nearly 88 % Z-drugs, hence in
the combined group of hypnotics/anxiolytics, drugs with
benzodiazepine structure were 31 % and Z-drugs 66 %.
When the ratio of multimorbid patients prescribed hyp-
notics/anxiolytics to the multimorbid patients in general
is calculated it increases steadily as the number of chronic
diseases within one patient increases (Table 7).
Of the 143,662 patients in the PHCCA cohort who did
not have multimorbidity, 4711 were prescribed a hypnotic
and/or an anxiolytic. On the other hand, 26,215 patients
out of 78,160 multimorbid patients were prescribed these
drugs. Thus, patients with multimorbidity were much more
likely to be prescribed a hypnotic and/or an anxiolytic com-
pared with patients without multimorbidity, OR = 14.9
(95 % CI = 14.4–15.4). Looking at men and women separ-
ately, women were more likely than men to be prescribed
these drugs, OR = 16.0 (95 % CI = 15.4–16.7) for women
versus OR= 12.7 (95 % CI = 12.0–13.3) for men, increasing
with age, as shown in Fig. 4.
The mean age of patients who contacted the primary
healthcare centres of the capital area was 36.4 years (men
35.7, women 37.0) compared with mean age of 36.8 years
(men 36.1, women 37.4) for the total Icelandic population.
Discussion
Main findings
In our comprehensive health services study covering con-
tacts within the primary healthcare in the capital area of





Prevalence of hypnotics/anxiolytics use (%)
All Men Women All Men Women
<1–19 848 389 459 1.4 1.3 1.5
20–29 2,748 994 1,754 8.0 6.2 9.6
30–39 4,071 1,480 2,591 12.2 9.0 15.3
40–49 4,881 1,626 3,255 17.7 12.0 23.0
50–59 6,154 2,094 4,060 24.3 16.9 31.5
60–69 5,382 1,938 3,444 28.1 20.7 35.1
70–79 3,948 1,388 2,560 35.4 26.7 42.9
80+ 2,894 1,013 1,881 28.9 24.7 31.9
Total 30,926 10,922 20,004 13.9 10.1 17.5
Prevalence of hypnotics/anxiolytics prescriptions in primary care stratified by age and sex during the period 1 Jan 2009 to 31 Dec 2012. The total number of patients is
shown in Table 2
Table 4 Incidence of hypnotics/anxiolytics prescriptions
Age Men Women All
groups N Cases pr 1,000 N Cases pr 1,000 pr 1,000
<1–19 30,982 107 3.5 30,051 128 4.3 3.9
20–29 15,950 215 13.5 18,305 375 20.5 17.2
30–39 16,310 268 16.4 16,981 542 31.9 24.3
40–49 13,498 258 19.1 14,121 485 34.3 26.9
50–59 12,398 287 23.1 12,902 509 39.5 31.5
60–69 9,351 231 24.7 9,808 340 34.7 29.8
70–79 5,197 139 26.7 5,969 201 33.7 30.4
80+ 4,103 102 24.9 5,896 118 20.0 22.0
Total 107,789 1,607 14.9 114,033 2,698 23.7 19.4
Incidence of hypnotics and/or anxiolytics prescriptions in men and women in
2011 according to age and sex. No prior use for 24 months
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Iceland during a four-year period we found the prevalence
of multimorbidity to be 35 %. The population behind these
contacts corresponds to approximately two-thirds of the
total Icelandic population. Both prevalence and the inci-
dence of hypnotic/anxiolytic prescriptions are high. More
than 80 % of those aged 40 years or older prescribed
hypnotics and/or anxiolytics are considered as being multi-
morbid, and 79 % of all incident patients are multimorbid.
Around 83 % of the incident patients prescribed hypnotics/
anxiolytics twice or more per year were multimorbid. In-
creased use of these drugs can at least partly, although not
solely be explained by the extent of multimorbidity. The use
of benzodiazepine anxiolytics (N05BA) and benzodiazepine
hypnotics (N05CD) in Iceland is similar to their usage in
other Nordic countries, but when comparing the use of the
benzodiazepine related drugs, i.e. Z-drugs (N05CF), it is 1.7
to 3.3 times higher in Iceland than in the other countries
[36]. In our study we found the incidence rate of hypnotic/
anxiolytic prescriptions in Iceland, i.e. 19.4 cases per 1000
inhabitants/year, to be similar to what has been reported in
a Norwegian study [32].
The prevalence of multimorbidity in our study is
similar to what has been reported elsewhere although
there are wide variations depending on the setting and
the age of the population being studied [1–3, 5, 8]. As
can be expected the prevalence increased with age.
However, a decrease was noticed in the oldest age
group. This could possibly in part be explained by the
“survival of the fittest”, i.e. those with the greatest
morbidity did not live long enough to reach this age.
Also, a considerable number of the oldest patients with
the greatest burden of frailty might have been cared for
by the geriatric services without contacting the primary
healthcare.
Table 5 Number of hypnotics/anxiolytics prescriptions in different age groups
Age All incident patients issued 1, 2–4 or 5+ prescriptions Multimorbid incident patients issued 1, 2–4 or 5+ prescriptions
groups 1 2–4 5+ All 1 2–4 5+ All
<1–19 163 52 20 235 82 28 7 117
20–29 373 177 40 590 225 124 29 378
30–39 484 244 82 810 348 188 62 598
40–49 418 232 93 743 335 187 78 600
50–59 431 273 92 796 362 243 81 686
60–69 298 213 60 571 262 198 54 514
70–79 166 128 46 340 151 119 44 314
80+ 92 104 24 220 86 101 23 210
Total 2,425 1,423 457 4,305 1,851 1,188 378 3,417














Fig. 1 Proportion of incident patients issued one, 2–4 or 5+
prescriptions. The proportion of incident patients in the primary
healthcare stratified by age who were prescribed hypnotics/anxiolytics
for the first time in 2011 (no prior prescriptions for 24 months) grouped






















Fig. 2 Diagnostic patterns among multimorbid incident patients.
Distribution of mental diagnoses, pain related diagnoses and other
diagnoses in multimorbid patients who initiated use of hypnotics/
anxiolytics in 2011, orderd by diagnoses and either one time use (1),
intermittent use (2–4) or regular use (5+)
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Strengths and limitations
The group of patients contacting the healthcare centres
during the four-year study period consisted of two-thirds
of the total population with approximately the same mean
age. It can be considered representative of the population
as a whole and this broad coverage strengthens the gener-
alisability of the study.
Almost all contacts within the primary care setting are
registered in a computerised medical record kept in the
same database as all issued prescriptions, most of them
sent electronically to the pharmacy. In this database
diagnoses are linked with the prescribed drugs through
the unique personal identifier (ID). This can be regarded
as strength. A previous Icelandic study found that the
Table 6 Level of morbidity in patients prescribed hypnotics/anxiolytics according to age and sex
Age
groups
Patients with no chronic
disease
Patients with one chronic
disease
Multimorbid patients – two or more chronic
diseases
ORs (with 95 % CIs) for the
likelihood of being prescribed a




Men Women No of
patients
Men Women No of
patients






































































All patients using a hypnotic, an anxiolytic or both either with no chronic condition, one chronic condition, or categorised as being multimorbid, with the odds















Fig. 3 Number of patients prescribed hypnotics and/or anxiolytics.
Patients prescribed hypnotics/anxiolytics according to age and
























Fig. 4 Odds ratios for being prescribed hypnotics and/or anxiolytics.
The ORs with 95 % CIs for the likelihood of a hypnotic and/or an
anxiolytic being prescribed for patients with multimorbidity
according to age and sex
Linnet et al. BMC Family Practice  (2016) 17:69 Page 7 of 10
use of antidepressants, anxiolytics and hypnotics was
most common among the socio-economically disadvan-
taged [37]. It may be considered a limitation that some
important variables such as smoking, socioeconomic sta-
tus and education are not systematically registered in
our medical records, as often is the case in questionnaire
based surveys. This has to be taken into account as we
are not able to adjust for some of these confounders in
our analysis. On the other hand, the medical records are
more reliable regarding diagnoses and drug prescriptions
in comparison to questionnaire based studies which can
be regarded as strength.
The choice of chronic conditions in our study (Table 1)
can be discussed. Most of them are distinct disease entities
but others grouped together as chapter based conditions,
e.g. cancer, mental health problems etc. This could pos-
sibly lead to underestimation of the prevalence of multi-
morbidity. On the other hand, the number of entities is
large and can be considered as strength, as it has been
shown that data for a minimum of twelve relevant chronic
diseases are needed in order to obtain a fair evaluation of
multimorbidity [3].
According to regulation in Iceland doctors are only
allowed to prescribe a month’s supply of benzodiaze-
pines and related drugs (Z-drugs). As a result, issuing
only one prescription for the patient amounts to fol-
lowing clinical guidelines. Thus the number of pre-
scriptions per patient per year indicates whether they
are one time, intermittent or regular users. This
strengthens the conclusions that can be drawn from
this material.
We do not have figures on non-adherence in this
study so prescriptions issued are the closest we come to
actual use. The rate of primary non-adherence in Iceland
was shown to be 6 % although not measured for hyp-
notics/anxiolytics [35]. This can be regarded a limitation.
In Iceland a GP-specialist referral system is not mandatory
as a requirement by the health authorities, so instead of
seeking medical attention at their general practitioner’s sur-
gery patients may go directly to a specialist without a refer-
ral from the GP. Thus they would not be registered in the
primary care material used in our study. This may be con-
sidered as a limitation.
Implications
It is well known that multimorbidity often leads to poly-
pharmacy. Most clinical guidelines refer to one specific
index disease, sometimes with comorbidities, but without
multimorbidity being used as a frame of reference. If these
guidelines are followed strictly in a multimorbid patient
one can end up with several drug related problems, e.g.
interactions [38]. Hypnotics/anxiolytics with their numer-
ous untoward effects may enhance the seriousness of the
problem. Mortality rises as patients become older, frailer
and more multimorbid, and untoward side effects and
interactions of drugs could have an additive effect. It has
been shown that the use of psychotropic drugs, hyp-
notics/anxiolytics included, and multimorbidity, jointly
increased the risk of falls in the elderly [39]. Further-
more, it was found that a considerable number of pa-
tients with pain related diseases as fibromyalgia had
both multiple chronic conditions and high use of sleep
aids and benzodiazepines [40].
Studies on the side effects of drugs and drug related
mortality are usually done in selected homogenous groups.
However, our study confirms, that most of the people
prescribed hypnotics/anxiolytics comprise a heterogeneous
group with multiple chronic conditions which increase the
risk of mortality, thereby limiting the possibility to explore
the potential effect of hypnotics/anxiolytics on mortality
separately without confounding factors influencing the re-
sult. Furthermore, it has been shown that more benzodi-
azepine prescriptions were issued for patients approaching
death than for a control cohort, indicating that the use of
these drugs was rather a consequence of disease discomfort,
than death being a result of the use of these drugs [21].
Regardless of whether benzodiazepines and Z-drugs have
a direct effect on mortality or not, the sum of all their dele-
terious effects may play a role in increased mortality and
overshadow their beneficial effects. It should therefore be a
priority to reduce the overprescribing of these drugs and to
encourage clinicians to design, implement and disseminate
guidelines with multimorbidity as a frame of reference in
order to allow them and their patients with multimorbidity
to make informed decisions about drug selection.
Conclusions
This study reveals that in Iceland, as in many other coun-
tries, both the prevalence and the incidence of hypnotic/
anxiolytic prescriptions are high. A considerable number
of incident patients were prescribed benzodiazepines and
Z-drugs for several times the recommended duration of
Table 7 Ratio of multimorbid patients prescribed hypnotics/










2+ 26,215 78,160 0.33
3+ 21,573 50,554 0.43
4+ 16,471 32,165 0.51
5+ 11,581 19,664 0.59
6+ 7,608 11,714 0.65
7+ 4,657 6,593 0.71
The number of chronic conditions in the group of patients prescribed
hypnotics/anxiolytics and the total population of multimorbid patients as well
as the ratio between the groups
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therapy which could develop into long-term drug taking
by these patients for an extended period, inconsistent with
accepted medical practice. Solely explaining this by linear
thinking, i.e. that “insomnia” leads to prescription of these
drugs is probably simplistic, as the majority of patients
prescribed these drugs are multimorbid having several
chronic conditions, mainly mental and pain related dis-
eases, which could lead to sleeping problems. There is a
variety of concern with long-term use of these drugs as
mentioned earlier in this paper, and their long-term effi-
cacy has not been clearly established with some doubt
having been cast on their short-term efficacy as well. Doc-
tors should be urged to focus their attention to patients’
problems in the context of their multimorbidity and to be
cautious when prescribing hypnotics for patients with
multiple chronic conditions, bearing in mind that a holistic
person focused approach is needed [4, 8, 41, 42]. They
should be encouraged to discuss the duration of therapy
with their patients before initiating benzodiazepine therapy
in order to enable informed decisions about when these
drugs should be discontinued. Multimorbidity per se is not
directly an indication for prescribing hypnotics, and sleep-
ing problems caused by the disease discomfort might in
many instances be solved with non-pharmacological
methods. It would be wise for family physicians to acquire
skills in these forms of treatment.
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